Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The application of the TLR7/8 (Toll Like Receptor) agonist gel (immune response helper)
resiquimod will enhance the immune response to the intradermal influenza vaccine in seniors
65-75 years of age.